Research programme: antibody drug conjugates - Glythera

Drug Profile

Research programme: antibody drug conjugates - Glythera

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glythera
  • Class Antibodies; Antineoplastics; Biological toxins; Immunoconjugates
  • Mechanism of Action Cell death stimulants; Cyclin dependent kinase 19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 26 Sep 2017 Glythera secures worldwide development and commercialisation license for CDK11 inhibitor payload series from Cancer Research UK for development of antibody-drug conjugates in the treatment of Cancer
  • 07 Jun 2017 Early research in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top